We found that delivering LPS after the ACT regimen increased the absolute number of donor CD8+ T cells (Fig. 6e) to host CD4+ T cells (Fig. 6f) in the spleen of irradiated mice 7 days after the treatment regimen, which likely explains why this approach effectively regresses B16F10 tumor. The gene discussed is CD8A; the disease is neoplasm.